drugset / Trial / NCT06390241

Avidination for RadionuclideTHerapy in Nonpalpable Breast Cancer

NCT06390241

NaSingle-groupOpen-labelTreatment

Summary

This is an interventional, open-label, non comparative phase 2 trial enrolling patients with nonpalpable breast cancer

Timeline

Start
2024-06-19
Primary completion
2025-01-30
Completion
2025-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 90Y DOTA-biotin Unknown 28 mbq Other
Subject 90Y DOTA-biotin Unknown 57 mbq Other
Subject 90Y DOTA-biotin Unknown 126 mbq Other
Subject Avidin Unknown 6 mg Other
Subject Avidin Unknown 10 mg Other

Indications